ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
56 announcements
Alkem incorporated a Saudi Arabian joint venture subsidiary, Alkem Pharma Company LLC, on 8 November 2026. It holds 51% after subscribing SAR 38.25 lakh, about ₹9.56 Crore.
Alkem Laboratories has scheduled its Board meeting for 12 Nov 2026 to consider Q2 and H1 FY27 unaudited results. No financial figures are disclosed in this advance notice.
Alkem Laboratories appointed Dr. Amrut Naik as CEO effective November 11, 2026. The Board designated him as Key Managerial Personnel at its November 3 meeting.
Alkem informed the exchange that US FDA completed inspection of its Mandva API facility with no Form 483 observations. The clean result confirms regulatory compliance.
Alkem Laboratories has initiated a forensic audit by Grant Thornton Bharat LLP following alleged misappropriation of funds by a former employee.
Alkem Laboratories Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements. This document details the company's equity structure.
Alkem Laboratories appointed Laxmikant Tiwari and Nilesh Vartak as Senior Management Personnel effective 12 October 2026. The appointments strengthen pharmaceutical operations and supply chain leadership.
Alkem Laboratories CFO Nitin Agrawal resigned effective 30 September 2026 for new opportunities. He was also a Key Managerial Personnel of the company.
Alkem Laboratories issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank for a Euro 49.5 Million term loan taken by its subsidiary, Occlutech Holding.
Alkem launches NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adults, for the first time in India. The once-daily drug is available in six tablet strengths.
Alkem Laboratories has appointed Dr. Shubhadeep Sinha as a Senior Management Personnel, effective September 15, 2026. This appointment falls under standard senior management disclosures.
Alkem launched Renocia Exo, a patented exosome-based hair growth serum. It expands the company's dermatology portfolio with a new follicle-support therapy.
Alkem Laboratories Limited concluded its 52nd Annual General Meeting on August 27, 2026. All resolutions proposed in the notice were duly approved by the members.
HDFC Mutual Fund disclosed an acquisition of 25,019 shares of Alkem Laboratories, increasing their aggregate holding to 5.017%. This triggers a mandatory regulatory disclosure.
Alkem reported Q1FY27 revenue of INR 3,740cr, up 11% YoY. India sales grew 10.3%, while International jumped 16%. EBITDA margin stood at 20.5%. Net profit declined 21.7% due to taxation.
Alkem Laboratories held an NCLT-convened meeting of equity shareholders to approve the Scheme of Amalgamation with Adroit Biomed Limited. The scheme received majority shareholder approval.
Alkem Laboratories' Board approved a new block at its Baddi manufacturing facility. The company will invest up to ₹75 Crore in this capacity expansion.
Alkem Laboratories reported an 11% revenue growth to ₹3,740.2 Crore for Q1FY27. Net profit stood at ₹520 Crore despite a 21.7% year-on-year decline.
Alkem Laboratories Ltd reported revenue from operations of ₹3,740 Cr (+10.9% YoY) and net profit of ₹521 Cr (-22.0% YoY) for Q1 FY27.
Alkem Laboratories announced the US FDA classified its Amaliya, Daman facility as 'Official Action Indicated'. Operations continue at the site.
Alkem Laboratories appointed Mr. Rajpal Singh Rana as Senior Vice President – Marketing & Sales, Acute Cluster, effective August 3, 2026.
Alkem Laboratories notified the exchange that it dispatched web-links for the FY 2025-26 Annual Report to unregistered shareholders. This filing fulfills Regulation 36(1)(b) compliance requirements.
Alkem Laboratories Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year ended 31st March, 2026.
Alkem Laboratories issued the notice for its 52nd Annual General Meeting, scheduled for August 27, 2026, alongside the Annual Report for FY 2025-26.
Dr. Jitendra Singh Huda has resigned from his position as Senior Management Personnel. The resignation is effective from July 23, 2026.
Alkem Laboratories will hold a board meeting on 14th August 2026 to consider and approve the standalone and consolidated unaudited financial results.
Alkem Laboratories completed the acquisition of a 51-55% stake in Swiss firm Occlutech Holding AG. Occlutech now becomes a step-down subsidiary of the company.
Alkem Laboratories acquired equity shares worth Rs. 1,100 Crore in its subsidiary, Alkem Medtech, via a rights issue. The investment supports Medtech's cardiovascular and orthopedic business.
Alkem Laboratories convened an NCLT-ordered shareholder meeting for August 17, 2026. Shareholders will consider the proposed scheme of amalgamation with Adroit Biomed Limited.
Alkem Laboratories received favorable CIT(A) orders for assessment years 2018-2023. The ruling deletes tax disallowances totaling Rs. 660.77 Crore, providing significant regulatory relief.